Rituximab biosimilar (Bionovis/The Instituto)

利妥昔单抗生物类似药 (Bionovis/The Instituto)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Bionovis/The Instituto)

Drug Alias Name利妥昔单抗生物仿制药 (Bionovis/The Instituto)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsGranulomatosis with PolyangiitisArthritis, RheumatoidLymphoma, Non-Hodgkin +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesBionovis The Instituto Vital Brazil

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBionovis The Instituto Vital Brazil

Active IndicationsN/A

Inactive IndicationsGranulomatosis with PolyangiitisArthritis, RheumatoidLymphoma, Non-Hodgkin +[4]

Other Information

ATC CodeL01XC02